Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Sandoz analysis sees $94 billion in potential Canadian drug savings through 2035

By Public Technologies
  • Sandoz Canada's Oct. 28, 2026 analysis estimates $94 billion in potential Canadian generic and biosimilar savings over 2026-2035.
  • More than 300 medicines will lose exclusivity or are already open to competition without market entry, representing $24 billion in annual branded-medicine value.
  • Opportunities include more than 250 generic medicines valued at $13 billion annually and more than 80 biological medicines valued at $11 billion.
  • Without timely market entry, payers could face $183 billion in cumulative spending on higher-cost branded treatments.
  • Realizing savings requires predictable regulatory processes, fewer market-entry barriers and policies supporting timely adoption of lower-cost alternatives.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief via CNW (Ref. ID: 202610280700CANADANWCANADAPR_C8002) on October 28, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.